Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC)

British Journal of Cancer

Volumn 110, Issue 11, 2014, Pages 2677-2687

  Skvortsov, S ^a   Dudas J ^a   Eichberger, P ^a   Witsch Baumgartner, M ^a   Loeffler Ragg, J ^b   Pritz, C ^a   Schartinger, V H ^a   Maier, H ^c   Hall, J ^d   Debbage, P ^a   Riechelmann, H ^a   Lukas, P ^a   Skvortsova, I ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^d EORTC DATA CENTER   (Belgium)

Author keywords

biomarker; head and neck cancer; Rac1; therapeutic target; treatment resistance; tumour recurrence

Indexed keywords

CETUXIMAB; CISPLATIN; MITOMYCIN; RAC1 PROTEIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CELLULAR DISTRIBUTION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; RAC1 GTP-BINDING PROTEIN; RNA, SMALL INTERFERING;

EID: 84901609325     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.221     Document Type: Article

References (35)

1. Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan P, Sherman EJ, Weber RS, Galvin JM, Schwartz DL, El-Naggar AK, Gillison ML, Jordan R, List MA, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29(suppl): abstr 5500.
2. Argiris A, Li Y, Forastiere A (2004) Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101: 2222-2229.
3. Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R (2006) A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 26: 585-590.
4. Begg AC (2012) Predicting recurrence after radiotherapy in head and neck cancer. Semin Radiat Oncol 22: 108-118.
5. Chen YW, Chu HC, Lin ZS, Shiah WJ, Chou CP, Klimstra DS, Lewis BC (2013) p16 stimulates CDC42-dependent migration of hepatocellular carcinoma cells. PLoS One 8: e69389.
6. Dudas J, Fullar A, Bitsche M, Schartinger V, Kovalszky I, Sprinzl GM, Riechelmann H (2011) Tumor-produced, active interleukin-1beta regulates gene expression in carcinoma-associated fibroblasts. Exp Cell Res 317: 2222-2229.
7. Fåhraeus R, Lane DP (1999) The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. EMBO J 18: 2106-2118.
8. Gastonguay A, Berg T, Hauser AD, Schuld N, Lorimer E, Williams CL (2012) The role of Rac1 in the regulation of NF-kappaB activity, cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer Biol Ther 13: 647-656.
9. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100: 407-420.
10. Gold KA, Lee HY, Kim ES (2009) Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115: 922-935.
11. Haddad RI, Shin DM (2008) Recent advances in head and neck cancer. N Engl J Med 359: 1143-1154.
12. Hitt R, Jimeno A, Rodriguez-Pinilla M, Rodriguez-Peralto JL, Millan JM, Lopez-Martin A, Brandariz A, Peña C, Cortés-Funes H (2004) Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer 91: 2005-2011.
13. Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y (2008) Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 149: 1009-1014.
14. Katz E, Sims AH, Sproul D, Caldwell H, Dixon MJ, Meehan RR, Harrison DJ (2012) Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget 3: 608-619.
15. Koch U, Radtke F (2007) Notch and cancer: a double-edged sword. Cell Mol Life Sci 64: 2746-2762.
16. Koh MS, Moon A (2011) Activation of H-Ras and Rac1 correlates with epidermal growth factor-induced invasion in Hs578T and MDA-MB-231 breast carcinoma cells. Biochem Biophys Res Commun 406: 25-29.
17. Lambrecht M, Dirix P, Van den BW, Nuyts S (2009) Incidence of isolated regional recurrence after definitive (chemo-) radiotherapy for head and neck squamous cell carcinoma. Radiother Oncol 93: 498-502.
18. Langendijk JA, Psyrri A (2010) The prognostic significance of p16 overexpression in oropharyngeal squamous cell carcinoma: implications for treatment strategies and future clinical studies. Ann Oncol 21: 1931-1934.
19. Lanning CC, Ruiz-Velasco R, Williams CL (2003) Novel mechanism of the co-regulation of nuclear transport of SmgGDS and Rac1. J Biol Chem 278: 12495-12506.
20. Levy AR, Johnston KM, Sambrook J, Donato B, Penrod JR, CorralM, ChasenM (2011) Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Curr Med Res Opin 27: 2253-2259.
21. Ma Q, Cavallin LE, Yan B, Zhu S, Duran EM, Wang H, Hale LP, Dong C, Cesarman E, Mesri EA, Goldschmidt-Clermont PJ (2009) Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc Natl Acad Sci USA 106: 8683-8688.
22. Massagué J (2008) TGFbeta in cancer. Cell 134: 215-230.
23. Mendoza-Catalan MA, Cristobal-Mondragon GR, me-Gomez J, del Valle-Flores HN, Coppe JF, Sierra-Lopez L, Romero-Hernández MA, del Carmen Alarcón-Romero L, Illades-Aguiar B, Castañeda-Saucedo E (2012) Nuclear expression of Rac1 in cervical premalignant lesions and cervical cancer cells. BMC Cancer 12: 116.
24. Michaelson D, Abidi W, Guardavaccaro D, Zhou M, Ahearn I, Pagano M, Philips MR (2008) Rac1 accumulates in the nucleus during the G2 phase of the cell cycle and promotes cell division. J Cell Biol 181: 485-496.
25. Raben D, Bianco C, Milas L, Ang KK (2004) Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin Radiat Oncol 14: 139-152.
26. Schaaij-Visser TB, Brakenhoff RH, Leemans CR, Heck AJ, Slijper M (2010) Protein biomarker discovery for head and neck cancer. J Proteomics 73: 1790-1803.
27. Schartinger VH, Falkeis C, Laimer K, Sprinzl GM, Riechelmann H, Rasse M, Virgolini I, Dudás J (2012) Neuroendocrine differentiation in head and neck squamous cell carcinoma. J Laryngol Otol 126: 1261-1270.
28. Skvortsov S, Jimenez CR, Knol JC, Eichberger P, Schiestl B, Debbage P, Skvortsova I, Lukas P (2011) Radioresistant head and neck squamous cell carcinoma cells: intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiother Oncol 101: 177-182.
29. Skvortsov S, Skvortsova I, Stasyk T, Schiefermeier N, Neher A, Gunkel AR, Bonn GK, Huber LA, Lukas P, Pleiman CM, Zwierzina H (2007) Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines. Mol Cancer Ther 6: 1898-1908.
30. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA, Lukas P (2008) Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8: 4521-4533.
31. Thomas J, Primeaux T (2012) Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma? Ann Diagn Pathol 16: 91-99.
32. Tselis N, Ratka M, Vogt HG, Kolotas C, Baghi M, Baltas D, Fountzilas G, Georgoulias V, Ackermann H, Zamboglou N (2011) Hypofractionated accelerated CT-guided interstitial (1)(2)Ir-HDR-brachytherapy as re-irradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer. Radiother Oncol 98: 57-62.
33. Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21(Suppl 7): vii252-vii261.
34. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) Head and neck cancer. N Engl J Med 328: 184-194.
35. Yalovsky S, Bloch D, Sorek N, Kost B (2008) Regulation of membrane trafficking, cytoskeleton dynamics, and cell polarity by ROP/RAC GTPases. Plant Physiol 147: 1527-2543.